Tumour stage, nodal stage and pathologic stage before and during the COVID-19 pandemic
| Variable | Period; no. (%) of patients | p value | ||
|---|---|---|---|---|
| Before COVID-19 pandemic n = 330 | During COVID-19 pandemic n = 320 | Overall n = 650 | ||
| Tumour stage | 0.9 | |||
| T1 | 132 (40.0) | 133 (41.6) | 265 (40.8) | |
| T2 | 114 (34.5) | 113 (35.3) | 227 (34.9) | |
| T3 | 39 (11.8) | 40 (12.5) | 79 (12.2) | |
| T4 | 28 (8.5) | 23 (7.2) | 51 (7.8) | |
| Missing | 17 (5.2) | 11 (3.4) | 28 (4.3) | |
| Nodal stage | 0.3 | |||
| Nx | 29 (8.8) | 16 (5.0) | 45 (6.9) | |
| N0 | 249 (75.4) | 248 (77.5) | 497 (76.5) | |
| N1 | 37 (11.2) | 37 (11.6) | 74 (11.4) | |
| N2 | 15 (4.5) | 18 (5.6) | 33 (5.1) | |
| Missing | 0 (0.0) | 1 (0.3) | 1 (0.2) | |
| Pathologic stage | 1.0 | |||
| I | 210 (63.6) | 196 (61.2) | 406 (62.5) | |
| II | 58 (17.6) | 59 (18.4) | 117 (18.0) | |
| III | 46 (13.9) | 47 (14.7) | 93 (14.3) | |
| IV | 16 (4.8) | 17 (5.3) | 33 (5.1) | |
| Missing | 0 (0.0) | 1 (0.3) | 1 (0.2) | |